Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Given Consensus Recommendation of “Hold” by Analysts

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) has been given an average rating of “Hold” by the thirteen ratings firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, five have issued a hold rating and seven have assigned a buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $19.7273.

BCYC has been the topic of a number of research analyst reports. JMP Securities set a $12.00 price objective on shares of Bicycle Therapeutics in a report on Friday, October 31st. Oppenheimer reiterated an “outperform” rating and set a $44.00 price target (down previously from $48.00) on shares of Bicycle Therapeutics in a research note on Monday, August 11th. Weiss Ratings reissued a “sell (e+)” rating on shares of Bicycle Therapeutics in a report on Monday, November 24th. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $11.00 target price (down previously from $27.00) on shares of Bicycle Therapeutics in a report on Friday, October 31st. Finally, Citizens Jmp upped their target price on Bicycle Therapeutics from $10.00 to $12.00 and gave the company a “market outperform” rating in a research report on Friday, October 31st.

Insider Activity at Bicycle Therapeutics

In other news, CEO Kevin Lee sold 3,231 shares of the stock in a transaction on Friday, October 3rd. The shares were sold at an average price of $8.41, for a total value of $27,172.71. Following the sale, the chief executive officer owned 475,310 shares in the company, valued at $3,997,357.10. This represents a 0.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last quarter, insiders have sold 8,527 shares of company stock valued at $71,738. 8.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Bicycle Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Assetmark Inc. grew its position in Bicycle Therapeutics by 74.9% during the 3rd quarter. Assetmark Inc. now owns 3,625 shares of the company’s stock worth $28,000 after purchasing an additional 1,552 shares during the period. Ausdal Financial Partners Inc. purchased a new stake in shares of Bicycle Therapeutics in the second quarter worth about $70,000. Sei Investments Co. acquired a new stake in Bicycle Therapeutics during the second quarter worth about $74,000. Virtus Investment Advisers LLC raised its position in Bicycle Therapeutics by 32.6% during the second quarter. Virtus Investment Advisers LLC now owns 10,821 shares of the company’s stock valued at $75,000 after acquiring an additional 2,659 shares in the last quarter. Finally, Ameriprise Financial Inc. acquired a new position in Bicycle Therapeutics in the second quarter valued at approximately $86,000. 86.15% of the stock is owned by hedge funds and other institutional investors.

Bicycle Therapeutics Stock Up 2.6%

Shares of Bicycle Therapeutics stock opened at $7.50 on Monday. The company has a 50 day moving average price of $7.51 and a 200 day moving average price of $7.65. The firm has a market capitalization of $520.28 million, a P/E ratio of -2.07 and a beta of 1.47. Bicycle Therapeutics has a 52 week low of $6.03 and a 52 week high of $21.50.

Bicycle Therapeutics (NASDAQ:BCYC) last released its earnings results on Thursday, October 30th. The company reported ($0.85) earnings per share for the quarter, topping the consensus estimate of ($1.09) by $0.24. The company had revenue of $11.73 million for the quarter, compared to the consensus estimate of $8.25 million. Bicycle Therapeutics had a negative net margin of 884.51% and a negative return on equity of 36.05%. As a group, research analysts anticipate that Bicycle Therapeutics will post -3.06 earnings per share for the current fiscal year.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.